5 results match your criteria: "Zulia University Medical School[Affiliation]"
Metabolic syndrome and related variables, insulin resistance, leptin levels, and PPAR-γ2 and leptin gene polymorphisms in a pedigree of subjects with bipolar disorder.
Braz J Psychiatry
January 2016
Department of Microbiology, Los Andes University Pharmacy School, Mérida, Venezuela.
Objective: Evidence points to a high prevalence of metabolic dysfunction in bipolar disorder (BD), but few studies have evaluated the relatives of subjects with BD. We conducted a cross-sectional study in an extended family of patients with BD type I.
Methods: The available relatives of the same family were interviewed (DSM-IV-R) and assessed in fasting conditions for body mass index, constituent variables of the metabolic syndrome (MS), leptin levels, insulin resistance index, and single nucleotide polymorphisms (SNPs) for the leptin receptor and promoter and PPAR-γ2 genes.
Article Synopsis
- Constipation is a common side effect of the antipsychotic drug clozapine (CLZ), affecting 25-60% of users.
- A diagnostic test using silver O-ring markers showed that patients on CLZ, either alone or with other antipsychotics, had significantly higher levels of gastrointestinal hypomotility compared to those on other antipsychotics.
- The study found that even some patients who did not meet clinical criteria for constipation still exhibited objective signs of hypomotility, confirming the impact of CLZ on gut function.
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
Schizophr Res
August 2010
Institute of Clinical Research Dr. Américo Negrette, Zulia University Medical School, Maracaibo, Venezuela.
Article Synopsis
- The study investigated how leptin's role influences metabolic issues in schizophrenia patients treated with clozapine, focusing on genetic variations in leptin-related genes.
- The research comprised two phases: first, analyzing the metabolic profiles and genetic SNPs of 56 patients; second, assigning 52 of these patients to receive either metformin or placebo for 14 weeks.
- Results indicated that while certain triglyceride levels were lowest in one genetic group, metformin treatment led to increased glucose levels in one genotype and a decrease in metabolic indicators in another, revealing complex responses based on genetic variations.
Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Schizophr Res
August 2009
Institute of Clinical Research Dr. Américo Negrette, Zulia University Medical School, Maracaibo, Venezuela.
Background: Clozapine is the most effective agent in treatment-resistant schizophrenia. However, it is frequently associated with excessive body weight (BW) gain, type 2 diabetes mellitus and hyperlipidemia. The antidiabetic metformin (MET) has proved effective to assist in BW control during olanzapine administration.
View Article and Find Full Text PDFCoagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.
Schizophr Res
August 2008
Institute of Clinical Research Dr. Américo Negrette, Zulia University Medical School, and University Psychiatric Hospital, Maracaibo, Venezuela.
Background: Clinical studies suggest that the second generation antipsychotics (APs) clozapine and olanzapine and to a lesser extent the typical antipsychotics may be associated with a procoagulant and proinflammatory state that promotes venous thromboembolism. We evaluated here several blood factors associated with coagulation and inflammation in AP-treated schizophrenia patients and their first-degree relatives.
Methods: Procoagulant factors (fibrinogen and plasminogen activator inhibitor [PAI-1]), the anticoagulant factor antithrombin III [AT-III], and inflammation-related factors (C-reactive protein [CRP] and leptin) were assessed in patients chronically treated with clozapine (n=29), olanzapine (n=29), typical APs (n=30) and first degree relatives of clozapine (n=23) and olanzapine subjects (n=11).